TNT Trial

Abstract In the Treating to New Targets (TNT) study, 10,001 patients with stable CHD and LDL‐C levels <130 mg/dL (3.4 mmol/L) were randomized to double‐blind therapy with either atorvastatin 10 or 80 mg/day and were followed for a median of 4.9 years. The primary endpoint was an occurrence of a first major cardiovascular event, defined as CHD death, nonfatal, non‐procedure‐related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. Mean LDL‐C levels achieved during treatment were 77 mg/dL (2.0 mmol/L) with atorvastatin 80 mg and 101 mg/dL (2.6 mmol/L) with atorvastatin 10 mg. A primary event occurred in 434 patients (8.7%) receiving atorvastatin 80 mg and 548 patients (10.9%) receiving atorvastatin 10 mg, representing a 2.2% absolute reduction in risk and a 22% reduction in risk of major cardiovascular events (HR = 0.78; CI = 0.69, 0.89; P < 0.001) in the high‐dose group. In conclusion, intensive lipid‐lowering therapy with atorvastatin 80 mg in patients with stable CHD provided significant additional clinical benefit beyond therapy with atorvastatin 10 mg.